United Therapeutics (NASDAQ: UTHR) Price Target Raised Amidst Clinical Progress and Legal Settlements
Cantor Fitzgerald raises its price target for United Therapeutics (NASDAQ: UTHR) to $850 from $700, implying 43.9% potential upside for the biotech stock. United Therapeutics expands its xenograft production capacity and receives FDA clearance for a Phase 2 trial of treprostinil SMI for pulmonary…